SLV310 is an antipsychotic compound used in the study of schizophrenia; it acts as an oral dopamine D2 receptor antagonist (Ki: 5 nM) and a serotonin reuptake inhibitor, effectively antagonizing apomorphine-induced climbing behavior and 5-HTP-induced serotonin syndrome-like behavior in mice (ED50 = 5.6 and 5.9 mg/kg, p.o., respectively).